Lilly CEO: GLP-1s May Redefine American Healthcare
TL;DR
Eli Lilly CEO David Ricks says GLP-1 drugs could be more transformative than AI, with strong weight‑loss and health benefits that could curb the roughly $1.4 trillion annual obesity‑related healthcare costs. He notes pricing moves and upcoming Medicare access (around $50 a month starting July) could broaden adoption, while Lilly’s tirzepatide program underscores how GLP‑1 therapies might reshape U.S. healthcare and chronic disease management.
- Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America Yahoo Finance
- New oral GLP-1 drug delivers up to 12% weight loss in 36 weeks Medical Xpress
- Oral Orforglipron for Obesity Management Drug Topics
- Medicine's Betul Hatipoglu researches GLP-1 pill for weight loss Case Western Reserve University
- New GLP-1 pill leads to 16% weight loss in a year and can be taken anytime thesun.co.uk
Want the full story? Read the original reporting
Read on Yahoo Finance